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Abstract
Comparing to data in patients with severe coronavirus diseases 2019 (COVID-19), there are
few studies on the prevalence anxiety and/or depression in patients with asymptomatic or
mildly symptomatic COVID-19. We investigated the clinical characteristics and the preva-
lence of anxiety and/or depression among asymptomatic or mildly symptomatic patients
with COVID-19 and monitored their mental health using an online assessment. An online
survey for monitoring and assessing the mental health of patients with COVID-19 using a
mobile phone was conducted. We used the Hospital Anxiety and Depression Scale to mea-
sure anxiety and/or depression levels. Of the 234 patients, 66 patients were asymptomatic
(28.2%), while the remaining 168 patients were mildly symptomatic. The prevalence of
anosmia (p = 0.001) and ageusia (p = 0.008) significantly decreased with the increasing
age. In addition, 19.8% and 14.0% patients had anxiety and/or depression in the first survey,
and one week after the first survey, respectively. Compared to patients without anxiety and/
or depression, those with anxiety and/or depression had a longer quarantine duration. We
found that anomia and ageusia were relatively common in the young age group. Further-
more, one-fifth asymptomatic or mildly symptomatic patients with COVID-19 had anxiety
and/or depression.
Introduction
By the end of 2019, early cases of coronavirus disease 2019 (COVID-19) were first reported in
Wuhan, China and COVID-19 had started spreading throughout China [1, 2]. The novel coro-
navirus causing of COVID-19 shares genomic sequence identity with both severe acute respi-
ratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus
(MERS-CoV) [3]. In addition, the epidemiology of COVID-19 is similar to that of severe acute
respiratory syndrome (SARS); hence, and the novel coronavirus has been named severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) [3, 4]. Despite undertaking strict
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quarantine measures, COVID-19 has spread rapidly worldwide. In March 2020, the World
Health Organization has declared the COVID-19 outbreak a pandemic.
In South Korea, the surge of confirmed cases was recognized from February 2020. To allo-
cate medical resources efficiently, the South Korean government classified patients according
to the severity of COVID-19, and asymptomatic or mildly symptomatic patients were admitted
to the community treatment centers (CTCs), non-hospital facilities for isolation and monitor-
ing. COVID-19 can manifest either as an asymptomatic infection or mild-to-severe pneumo-
nia. Data pertaining to the clinical characteristics and mental health support are limited in
patients who asymptomatic or had mild symptoms, who constitute the base of the disease pyr-
amid, comparing to data in patients with severe COVID-19 symptoms [5].
Therefore, we analyzed the clinical characteristics of asymptomatic or mildly symptomatic
patients with COVID-19. We also monitoring their mental health using an online assessment
during the COVID-19 outbreak.
Methods
Patients and study settings
We included patients admitted to the CTC with asymptomatic or mildly symptomatic
COVID-19 based on the early warning score of<3 for SARS-CoV-2 infected patients [6]. In
this study, patients referred to other hospitals due to a symptom change during the isolation
were excluded.
A written informed consent was obtained from each patient who agreed to participate in
the online mental health assessment. Missing data were collected using telephone interviews
by well-trained doctors. This study was approved by the Institutional Review Board of Sever-
ance Hospital (Seoul, South Korea).
We conducted an online survey for the monitoring of patients with COVID-19 from
March 15 to April 10, 2020. And, we also examined the mental health of the patients using an
online assessment once a week for 2 weeks during the quarantine period.
Definition
Reverse transcription polymerase chain reaction (RT-PCR) assays for the E (envelope protein),
RdRP (RNA-dependent RNA polymerase), and N (nucleocapsid protein) genes were per-
formed with the Allplex™ 2019-nCoV Assay (Seegene Inc., Seoul, South Korea) using nasopha-
ryngeal swab samples. Negative RT-PCR results were re-tested by the RT-PCR after 24 hours;
positive RT-PCR results were re-tested by RT-PCR after 7days; and inconclusive RT-PCR
results were re-tested by RT-PCR after 3days.
Results of the RT-PCR assays were expressed as the cycle threshold (Ct) value. Negative
RT-PCR results were defined as Ct values�40. Negative conversion was defined as two conse-
cutive negative RT-PCR results with a 24-hour interval.
The patients were divided into 4 groups by age patients aged <20 years were categorized in
group A; those aged 20–39 years were categorized in group B; those aged 40–59 years were cat-
egorized in group C; and those aged�60 years categorized in the group D.
The Hospital Anxiety and Depression Scale (HADS), a self-assessment scale using an online
survey, was used to measure the levels of anxiety and depression [7]. Anxiety and depression
were assessed respectively using the 7-item subscales, which were scored from 0 to 21 for each
subscale. Scores of 11–21 indicate an abnormal case (probable case of anxiety or depression)
[8]. HADS was administered after the second week of the quarantine period, and a follow-up
survey was conducted one week after the first survey.
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Statistical analysis
All variables are expressed as the mean ± standard deviation (SD), unless otherwise indicated.
Statistical significance was set at the level of p< 0.05. Categorical variables were compared
using χ2 test, and continuous variables with normal distributions were compared using the
Student’s t-test. Differences in the four age groups were evaluated by one-way ANOVA with
Tukey’s multiple comparison test. All statistical analyses were performed using IBM SPSS Sta-
tistics for Windows, version 23.0 (IBM Corp., Armonk, NY, USA).
Results
Clinical characteristics
An analysis was conducted on 234 of 247 patients with COVID-19 excluding 13 patients who
referred to other hospitals due to a symptom change during the isolation. The mean age of all
patients was 37.78 ± 15.57 years, and 93 of the study participants were male (39.7%). Among
them, there were 66 (28.2%) asymptomatic patients with COVID-19.
Clinical characteristics of the patients stratified by age are summarized in Table 1. Fever was
present in 17.5% of the patients. The most common symptoms were myalgia (23.9%), anosmia
(20.1%), and cough (19.7%); chest pain (1.7%) and vomiting (1.7%) were uncommon. Anosmia
(p = 0.001) and ageusia (p = 0.008) significantly decreased with increasing age. In addition, nasal
stuffiness (p = 0.027), dizziness (p = 0.020), and headaches (p = 0.010) showed a statistically signif-
icant decrease in older age groups. Fig 1 shows the distribution of age according to symptom sta-
tus (anosmia and ageusia). Patients with anosmia were younger than those without anosmia
(mean age: 30.60 ± 12.55 vs. 39.59 ± 15.76 years, p< 0.001); patients with ageusia were younger
than those without symptoms (mean age: 31.43 ± 14.22 vs. 38.97 ± 15.56 years, p = 0.005).
The quarantine time course of patients without negative conversion according to age is
shown in Fig 2. The proportion of patients with negative conversion was significantly higher
in the young age group (< 20 years) than in the old age group (>40 years) (p = 0.014).
HADS survey for mental health care
Table 2 shows the results of the HADS survey for mental health care. Of the 234 patients, 146
patients (62.4%) participated and finished the questionnaires more than once; 66 patients
(45.2%) completed the questionnaires twice and 80 patients (54.8%) participated in one of the
two surveys. In the first survey, 25 of the 126 patients (19.8%) had anxiety and/or depression
(13 cases of anxiety and 20 cases of depression). In the second survey, 12 of the 86 patients
(14.0%) had anxiety and/or depression (3 cases of anxiety, and 11 cases of depression). Among
patients who finished the questionnaires twice, the mean anxiety score in the second survey
decreased compared to that in the first survey.
In the first survey, age and quarantine days were compared between patients with and with-
out anxiety and/or depression. Compared to patients (101/126,80.2%) without anxiety and/or
depression, those with anxiety and/or depression (25/126, 19.8%) had a longer duration of
quarantine (25.52 ± 4.78 vs. 23.32 ± 5.17 days; p = 0.007). Patients with anxiety and/or depres-
sion were older (than those without anxiety and/or depression 38.28 ± 14.22 vs. 35.76 ± 15.76
years; p = 0.463), but the difference was not statistically significant. In the second survey, there
were no significant differences in age and quarantine days between the two groups.
Discussion
In the present study, we provided the demographic and clinical data of 234 asymptomatic or
mildly symptomatic patients with COVID-19 who were only isolated at the CTC and were not
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administered any COVID-19 treatment. None of the 234 individuals developed pneumonia,
and 66 patients (28.2%) were asymptomatic during the isolation.
The precise interval during which a patient with COVID-19 is infectious is uncertain. It
appears that SARS-CoV-2 can be transmitted prior to the onset of symptoms and throughout
the course of illness. Moreover, the transmission of SARS-CoV-2 from asymptomatic patients
has also been reported [9, 10]. In addition, the highest viral RNA levels were detected from
upper respiratory specimens soon after symptom onset compared; the levels subsequently
declined over the course of the illness [11–13]. Therefore, to control this pandemic, rapid and
Table 1. Comparisons of demographic and clinical characteristics according to stratified age groups in asymptomatic or mildly symptomatic patients with
COVID-19.
Variables Total (n = 234) Group A (n = 33) Group B (n = 97) Group C (n = 85) Group D (n = 19) p value
Age, years 37.78 ± 15.57 18.03 ± 2.53 27.48 ± 5.23 51.54 ± 5.03 63.11 ± 2.18
Male, yes 93 (39.7) 15 (45.5) 49 (50.5) 23 (27.1) 6 (31.6) 0.011
Smoker 22 (9.4) 4 (12.1) 11(11.3) 5 (5.9) 2 (10.5) 0.349
Comorbidity
Hypertension 15 (6.4) 0 (0.0) 5 (5.2) 8 (9.4) 2 (10.5) 0.044
Diabetes 2 (0.9) 0 (0.0) 0 (0.0) 1 (1.2) 1 (1.2) 0.055
COPD 3 (1.3) 0 (0.0) 0 (0.0) 2 (2.4) 1 (5.3) 0.046
Old tuberculosis 3 (1.3) 0 (0.0) 0 (0.0) 3 (3.5) 0 (0.0) 0.195
Asthma 3 (1.3) 0 (0.0) 2 (2.1) 1 (1.2) 0 (0.0) 0.914
Allergy 12 (5.1) 4 (12.1) 6 (6.2) 2 (2.4) 0 (0.0) 0.018
Chronic kidney disease 1 (0.4) 0 (0.0) 1 (1.0) 0 (0.0) 0 (0.0) 0.641
Chronic liver disease 3 (1.3) 0 (0.0) 0 (0.0) 3 (3.5) 0 (0.0) 0.195
Malignancy 7 (3.0) 0 (0.0) 0 (0.0) 5 (5.9) 2 (10.5) 0.003
Symptomatic 120 (51.3) 20 (60.6) 53 (54.6) 39 (45.9) 8 (42.1)
Symptomatic, early relief� 48 (20.5) 3 (9.1) 20 (20.6) 22 (25.9) 3 (15.8)
Asymptomatic 66 (28.2) 10 (30.3) 24 (24.7) 24 (28.1) 8 (42.1) 0.499
Fever 41 (17.5) 11 (33.3) 14 (14.4) 14 (16.5) 2 (10.5) 0.068
Chill 37 (15.8) 7 (21.2) 10 (10.3) 16 (19.3) 4 (22.2) 0.482
Cough 46 (19.7) 6 (18.2) 25 (25.8) 11(12.9) 4 (21.1) 0.351
Sputum 40 (17.1) 5 (15.2) 21 (21.6) 11 (12.9) 3 (15.8) 0.477
Sore throat 31 (13.2) 1 (3.0) 16 (16.5) 12 (14.1) 2 (10.5) 0.473
Rhinorrhea 33 (14.1) 3 (9.1) 21 (21.6) 7 (8.2) 2 (10.5) 0.287
Nasal stuffiness, [T��] 37 (15.8) 4 (12.1), [a, b] 26 (26.8), [a] 6 (7.1), [a, b] 1 (5.3), [b] 0.027
Dizziness 11 (4.7) 3 (9.1) 7 (7.2) 1 (1.2) 0 (0.0) 0.020
Headache 11 (4.7) 8 (24.2) 24 (24.7) 10 (11.8) 1 (5.3) 0.010
Anosmia, [T��] 47 (20.1) 10 (30.3), [a] 27 (27.8), [a] 9 (10.6), [a, b] 1 (5.3), [b] 0.001
Ageusia 37 (15.8) 9 (27.3) 19 (19.6) 7 (8.2) 2 (10.5) 0.008
Myalgia 56 (23.9) 6 (18.2) 15 (15.5) 29 (34.1) 6 (31.6) 0.013
Fatigue 30 (12.8) 6 (18.2) 15 (15.5) 7 (8.2) 2 (10.5) 0.122
Chest pain 4 (1.7) 2 (6.1) 2 (2.1) 0 (0.0) 0 (0.0) 0.031
Vomiting 4 (1.7) 2 (6.1) 0 (0.0) 2 (2.4) 0 (0.0) 0.348
Diarrhea 15 (6.4) 2 (6.1) 8 (8.2) 3 (3.5) 2 (10.5) 0.804
COPD, chronic obstructive lung disease
�Early relief was defined as patients who have lost symptoms within 7 days.
��The same letters indicate non-significant difference between the groups based on Tukey’s multiple comparison test.
Patients were divided into Group A, B, C, and D (aged <20, 20–39, 40–59, and�60 years, respectively)
Continuous variables are shown as the mean ± standard deviation (SD) and categorical variables, as numbers (percentage).
https://doi.org/10.1371/journal.pone.0242130.t001
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large-scale RT-PCR testing needs to be conducted for identifying asymptomatic patients with
COVID-19 through close contact tracing.
In our patients, the most common symptom was myalgia, followed by anosmia and cough,
while fever and sputum production were observed in 17.5% and 17.1% patients, respectively.
We found that mildly symptomatic patients in the young age group (<40 years) were prone to
have anosmia and ageusia during isolation, and these symptoms were accompanied by nasal
stuffiness, dizziness, or headaches. Particularly, smell and taste dysfunctions have been
reported as uncommon symptoms of COVID-19 in early Chinese reports. In a previous study,
the frequency of neurological manifestation was analyzed in 214 patients with COVID-19;
anosmia and ageusia were noted in 11 (5.1%) and 12 (5.6%) patients, respectively [14]. Some
studies conducted in Europe have detected a very high frequency (19.4%–88%) of chemosensi-
tive disorders in patients with COVID-19 [15–18].
Anosmia has been reported in SARS [19] and other coronavirus infections [20]; however, it
is a rare occurrence. Anosmia might be caused due to the direct damage of the olfactory and
gustatory receptors caused by the virus [21]. In our study, even mildly symptomatic patients
had anosmia or ageusia in the early stage of COVID-19, and patients with anosmia were youn-
ger than those without anosmia. In other studies, the olfactory and gustative alterations were
reported more frequently in the early stages of the infection and in mildly symptomatic
patients [15–17], which is consistent with our study results. Therefore, anosmia and ageusia
could represent crucial symptoms for suspecting SARS-COV-2 infection.
In our study, the prevalence of anxiety and/or depression was 19.8% among asymptomatic
or mildly symptomatic patients with COVID-19. Only limited studies have reported mental
health care of asymptomatic or mildly symptomatic patients with COVID-19. The negative
impact of emerging infectious diseases has resulted in mental health sequelae, including dis-
tress, insomnia, anxiety, depression, and posttraumatic stress disorder [22]. A recent meta-
analysis and empirical analysis of psychological burden scales to assess the impact of isolation
Fig 1. Distribution of age according to patients without or with symptoms. A. Patients with anosmia (n = 47), B. Patients with ageusia (n = 37).
https://doi.org/10.1371/journal.pone.0242130.g001
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Table 2. Results of Hospital Anxiety and Depression Scale survey in asymptomatic or mildly symptomatic patients with COVID-19.
Variables First survey (n = 126) Second survey (n = 86) p value
Age, years 36.2 ± 15.26 34.46 ± 15.2 0.403
Quarantine period, days 23.75 ± 5.16 30.56 ± 4.56 -
Anxiety score 5.38 ± 3.80 4.37 ± 3.13 0.036
Depression score 6.70 ± 4.02 6.10 ± 4.21 0.302
Abnormal cases� 25a/126 (19.8) 12b/86 (14.0) 0.267
Consultation with experts 3/126 (2.4) 1/86 (1.2) 0.648
Patients with both tests (n = 66)
Age, years (36.5 ± 15.6)
Quarantine period, days�� 23.85 ± 4.64 30.85 ± 4.64 -
Anxiety score�� 4.88 ± 3.18 4.21 ± 2.90 0.211
Depression score�� 6.20 ± 3.93 6.20 ± 3.86 1.000
�A score of 11 or higher indicated probable presence of the mood disorder.
a13 cases in anxiety scores, and 20 cases in depression scores.
b3 cases in anxiety scores, and 11 cases in depression scores.
��It shows only the value of patients who conducted both surveys (n = 66).
Continuous variables are shown as the mean ± standard deviation (SD) and categorical variables, as numbers (percentage).
https://doi.org/10.1371/journal.pone.0242130.t002
Fig 2. Quarantine time course of patients without negative conversion according to age (p = 0.014).
https://doi.org/10.1371/journal.pone.0242130.g002
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precautions on the quality of life showed that the effect in all studies, except one, was negative
and that isolated patients are the worst affected [23].
We found that patient who completed the survey twice exhibited decreased anxiety scores,
but it was not statistically significant. After the first and second surveys, general physicians
from the CTC consulted patients with anxiety and/or depression over the phone; there was a
decrease in the patients’ psychological distress. In total, 4 patients wanted to consult a psychia-
trist (3 patients from the first survey and 1 patient from the second survey). One of 4 patients
who wanted expert counseling took a medicine (anxiolytics), and the others improved only
through on-line supportive psychotherapy.
In the early stages of the SARS outbreak, a range of psychiatric conditions, including high
levels of stress, depressive symptoms, anxiety, insomnia, nightmares, and poor concentration
were reported by SARS patients [24]. These psychiatric morbidities might be still significant
even after the physical recovery of SARS-infected individuals [25]. Psychosocial consequences
have also been reported in COVID-19 patients [26].
Furthermore, Patients who had recovered from SARS and a history of psychiatric consulta-
tions in the acute phase of illness had a higher risk for psychological distress later [22]. There-
fore, patients with SARS-CoV-2 infection should be provided timely and focused mental
health support after their discharge from quarantine. On the other hand, the mental health
may be serious not just for the patients but also for others who are in the general population,
among health care workers, and in vulnerable population [27, 28]. The COVID-19 pandemic
has led to a vigorous and multifaceted response from psychiatrists and other professionals.
The effect of pandemic on mental health will remain for a long time after COVID-19 out-
breaks. Therefore, there is a need for in-depth research and guidelines of management in the
general or vulnerable population [27].
who are already vulnerable to biological or psychosocial stressors, health care workers, and
even people who are following the news through numerous media channels in pandemics.
This study has some limitations. First, it is limited by its small sample size and using simple
scale for mental health check. The COVID-19 outbreak is leading to widespread fear, anxiety,
and other psychological distress. Therefore, it is necessary to apply various psychometric assess-
ment for an in-depth analysis. Further large-scale and in-depth studies of mental health care in a
diverse clinical spectrum of patients with SARS-CoV-2 infection are required. Second, the Ct val-
ues were not collected at the time of diagnosis. Therefore, we could not analyze the serial changes
in Ct values for the three genes in asymptomatic or mildly symptomatic patients with COVID-
19. Third, this study did not include the clinical outcomes of all the patients because some of the
patients were referred to another CTC at the end of the quarantine period; hence, further analysis
would be needed. Fourth, we collected the mental health data of patients using a mobile phone-
based survey, and, for patients who could not use their mobile phones, physicians asked direct
questions by telephone. Therefore, there might be a data discrepancy between the two groups.
This is the first study to describe the mental health status in asymptomatic or mildly symp-
tomatic patients with COVID-19 in South Korea. We found that 66 (28.2%) patients were
asymptomatic and that anomia and ageusia were relatively common in the young age group.
The demographic and clinical characteristics of asymptomatic or mildly symptomatic patients
with COVID-19, including the mental health status presented in this study can contribute in
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